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SUMMARY 
Title: Polycystic ovary syndrome in adolescence 
Name: TomislavPuževski 
            Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in 
women of reproductive age, a demographic which includes adolescents as well. 
Accurate data on the prevalence and incidence in the adolescent population is 
unavailable. This is largely due to the variable nature of this disorder, uncertain 
etiology and diagnostic challenges that often lead to the late diagnosis of PCOS, 
typically during adulthood. 
The diagnosis of PCOS should be considered in any adolescent female with a main 
complaint of hirsutism, menstrual irregularity and often followed by obesity. In general 
these are not rare complaints for adolescent females. There are also long term 
consequences associated with PCOS, which, in addition to infertility include type 2 
diabetes mellitus, metabolic syndrome and possibly cardiovascular disease and 
endometrial carcinoma.Acanthosis nigricans, treatment-resistant acne, scalp hair loss 
or hyperhidrosis may alternatively present as the chief complaint, although these 
features are not always present.  
Treatment for an adolescent with PCOS is primarily directed at the major clinical 
manifestations and complaints. Several treatment options have been developed for 
each of these and some options address more than one symptom. However, the 
initial measure is to adopt a healthy lifestyle, with a strong focus on reducing the body 
weight in obese patients, which, in combination with some other therapeutic 
procedures, leads to an optimal effect of therapy. It also helps reduce the risk of 
certain cancers and improve the quality of life.Targeting of the etiologic factor is not 
yet possible, although pathophysiologic explanation for it remains an area of intense 
study. 
This review focuses on the pathophysiology, presentation and diagnosis of PCOS in 
adolescence together with its clinical management. 
Keywords: Polycystic ovarian syndrome, adolescent, menstrual irregularity, 
hyperandrogenism, obesity 
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INTRODUCTION 
            In 1935, Stein and Leventhal published a case series of seven women with 
amenorrhea, hirsutism, and bilateral polycystic ovaries, a condition that later came to 
be known as polycystic ovary syndrome (PCOS). Since its original description, the 
definition has undergone several revisions [1]. 
 PCOS is now recognized as the most common endocrine disorder in females 
affecting 5-10% of those of reproductive age [2]. The concept of polycystic ovary 
syndrome has progressed from primarily a reproductive disorder to largely a 
metabolic disorder. It has also been expanded from a disorder that presents at 
menarche at ends at menopause to a disorder that may be present form birth to old 
age. Characteristics of disorder are high levels of androgens from the ovary, 
anovulatory cycles and polycystic ovaries on ultrasound. Insulin resistance and 
obesity are oftenly associated with the syndrome. 
 Symptoms of hyperandrogenism which include excessive hair growth on the face 
and body (hirsutism), acne, alopecia as well as irregular or absent periods appear 
around the onset of puberty. Most women with PCOS have some level of insulin 
resistance and experience weight gain together with difficulties losing weight that 
additionally worsens clinical picture. The problem is in recognizing these symptoms 
on time because they are frequent in adolescent girls without PCOS and can be 
easily overlooked.It is estimated that PCOS is present in around 25% of adolescent 
population [3]. 
Metabolic disturbances which follow PCOS lead tohigher risk for type 2 diabetes 
mellitus, metabolic syndrome, cardiovascular diseases and endometrial cancer.This 
is the reason that PCOS has been recognized as a leading health risk among the 
woman of reproductive age.  
Early detection in adolescence could prevent both emotional and financial suffering, 
as well as prevention of metabolic consequences in the future life of individual. 
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PATHOPHYSIOLOGY OF PCOS 
              PCOS is characterized by intraovarian androgen excess, which seems to be 
responsible for not only the cutaneous manifestations of the syndrome, but also both 
anovulation and the polycystic appearance of the ovaries. Intraovarian androgen 
excess stimulates the growth of small follicles but interferes with selection of a 
dominant follicle [4].The resultant excess of small follicles arrested in development 
yields the “polycystic” appearance of the ovaries.  Historically, PCOS was considered 
to result from a disorder of hypothalamic-pituitary gonadotropin secretion. More 
recently, considerable evidence suggests that PCOS is fundamentally a disorder of 
ovarian steroidogenesis. In addition, there is evidence that the steroidogenic 
dysfunction is closely associated with a metabolic disorder, a key component of 
which is insulin resistance. 
Abnormal intraovariansteroidogenesis 
Recent studies have preferred the concept where the anovulation of PCOS is 
attributable to intraovarian androgen excess, which arises from functional ovarian 
hyperandrogenism (FOH) [4,5].The intraovarian level of androgens in FOH is higher 
than in most adrenal causes of androgen excess.Significantintraovarian androgen 
excess, stimulate excessive growth of small ovarian follicles while inhibiting follicular 
maturation necessary for the development of dominant follicle [10]. It also causes 
thecal and stromal hyperplasia. These androgen effects cause the anovulatory 
symptoms and the polycystic appearance of the ovaries [11]. Similar ovarian changes 
are found in poorly controlled classic congenital adrenal hyperplasia, which, thus, 
cause secondary PCOS.  
Eighty percent or more cases of PCOS appear to arise from dysregulation of ovarian 
androgen secretion. The dysregulation of steroidogenesis is postulated to result from 
imbalance among the various intrinsic and extrinsic factors involved in the modulation 
of LH action in the ovary or ACTH action in the adrenal cortex.  In the ovary, the 
major site of dysregulation occurs in theca cell cytochrome P450c17, which has 17-
hydroxylase and 17,20lyase activity. The latter enzymatic activity is the rate-limiting 
step in androgen formation both in the ovaries and adrenal glands [5]. 
This combination of deficits seems to account for the characteristic hyper- 
responsiveness of excessive 17-hydroxyprogesterone to GnRH agonist. 
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Granulosa cells also exhibit steroidogenic dysregulation [5].They are excessively 
responsive to FSH, mostly at high dosage. The increased responsiveness of the 
granulosa cells to gonadotropins may be, in part, due to an increase in the 
percentage of follicles that are recruited to enter the growth cycle and in part because 
of intrinsic granulosa cell dysfunction [12]. This seems to contribute for the tendency 
of women with PCOS to develop ovarian hyperstimulation syndrome during fertility 
treatment. This concept is supported by a proof of persistently abnormal granulosa 
cell function after long-term suppression of ovarian androgen excess [13]. 
Abnormal gonadotropin secretion 
Excessive luteinizing hormone (LH) relative to follicle-stimulating hormone (FSH) was 
the first laboratory abnormality identified in classic PCOS. Despite being a common 
characteristic of PCOS it is not included into current diagnostic criteria. Elevated LH 
is thought to play a role in the pathogenesis of PCOS by increasing androgen 
production and secretion by ovarian theca cells [5]. 
The latest research suggest that excess in LH may result from abnormal sex steroid 
feedback at the hypothalamic level rather than the cause of androgen excess [6]. 
This evidence indicates that the modest rise in androgen levels in patients with 
PCOS paradoxically stimulates LH pulsatility. This is because women with PCOS 
were less responsive to luteal phase levels of estradiol and progesterone than normal 
[7]. Further examination showed that antiandrogen treatment normalized the 
inhibitory effect of progesterone on LH pulse frequency [8].These findings suggest 
that androgen excess interferes with the hypothalamic inhibitory feedback of female 
hormones, principally progesterone. 
Other lines of evidence also argue against the hypothesis that PCOS is primarily 
caused by abnormal pituitary function. About half of patients with PCOS, principally 
obese patients, do not have elevated LH levels or abnormal gonadotropin responses 
to gonadotropin-releasing hormone (GnRH) agonist testing [6, 9]. Furthermore, about 
half of PCOS subjects with a documented ovarian source of hyperandrogenism were 
demonstrated to have normal LH levels and LH responses to a GnRH agonist test, 
also suggesting that their ovarian dysfunction is independent of LH excess.   
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Disturbances in insulin secretion 
The compensatory, insulin-resistant hyperinsulinism, is an important extrinsic factor 
in the steroidogenic dysregulation of PCOS [14, 15].There are many evidence to the 
metabolic effects of insulin excess. Insulin resistance is common in PCOS and is 
excessive for the degree of adiposity [14-16].Hyperinsulinism tends to account for for 
the epidermal hyperplasia that causes acanthosis nigricans. Beside contributing to 
pituitary LH excess, it potentially also affects hypothalamic GnRH release [17]. 
Clinically all forms of insulin resistance, from rare lipodystrophies to common type 2 
diabetes mellitus, are related with PCOS. The evident increase in prevalence in type 
1 diabetes mellitus among PCOS women may be explained by relative peripheral 
hyperinsulinemia [18]. Insulin- lowering treatments particularly improve ovarian 
function. 
 
 A summarymodel of PCOS pathogenesis  
The core of PCOS is functional ovarian hyperandrogenism. This can be a reason for 
all the clinical features that characterize PCOS: hirsutism, anovulation, and polycystic 
ovaries. The hyperinsulinemia found in about half of cases,seems to act selectively 
on the ovary, regardless of resistance to the metabolic effects of insulin, so as to both 
upregulate androgen production in response to LH and stimulate adipogenesis [5]. 
Secondarily, two vicious cycles of feed-forward effects occur. The modest 
hyperandrogenemia causes secondary LH elevation by interfering with female 
hormone negative feedback. In the presence of insulin excess, this LH excess 
exacerbates the ovarian dysfunction. Insulin-resistant hyperinsulinemia also 
stimulates adiposity, which in turn aggravates the insulin-resistant state [14]. 
In most PCOS, the cause of ovarian hyperandrogenism seems to be intrinsic, and 
this appears to be the case for significant insulin resistance. In the absence of 
intrinsic ovarian dysfunction,hyperandrogenemia of extra-ovarian origin (adrenal or 
peripheral sources) is an unusual cause of anovulation and polycystic ovaries. 
Several inborn and environmental factors are known that can contribute to ovarian 
hyperandrogenism and/or insulin resistance. Polycystic ovaries, androgen levels, 
andinsulin resistance are hereditary traits while environmental factors include obesity 
and intrauterine androgen exposure[5]. 
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ETIOLOGY 
PCOS is a complex genetic disorder which develops in carriers of susceptible genetic 
variations and as a response to complex environmental influences [20, 21].It seems 
to be a congenital disorder that is first diagnosable at the onset of puberty.A genetic 
basis for the disorder has been suggested by familial clustering cases [22]. 
Two studies propose that polycystic ovaries appear to occur as an autosomal 
dominant trait [23, 24]. In almost half of sisters of women with PCOS an elevated 
plasma testosterone level was found. However, only half of these sisters had 
symptoms of menstrual irregularity. Most adolescent with a polycystic ovary have 
either a mother with a polycystic ovary, or a father with metabolic syndrome [25]. 
The widespread concept is that PCOS is the result of one of a number of intrinsic 
ovarian genetic traits that interact with one or more other congenital or environmental 
factors to cause dysregulation of steroidogenesis. This is essentially a "two-hit 
model," that is, a minimum of two interactive factors is required for the disorder to 
become manifest. 
The underlying cause for androgen excess is still unclear. Multiple subclinical 
steroidogenic defects have been reported to be risk factors for the syndrome[26]. 
Lately, theca cells were found to retain their capacity for excessive steroidogenesis 
through many doublings in culture, supporting the intrinsic mechanism [27]. 
Recently, evidence for a developmental basis for the syndrome has become visible 
too. Prenatal androgen excess or perinatal insults that cause intrauterine growth 
retardation may predispose to obesity, insulin resistance, and androgen excess later 
in life [28, 29]. 
An increase in insulin resistance sometimes follows the subtle increase in androgen 
levels that occur in ovulatory women with polycystic ovaries [30]. Accordingly, insulin 
resistance may develop in parallel with androgen excess.  The association of PCOS 
with insulin resistance [31] and obesity accounts for the predisposition of these 
women to metabolic syndrome[32] and type 2 diabetes mellitus [33]. 
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CLINICAL FEATURES 
The most common complaints in adolescent girls with PCOS are hirsutism and 
menstrual irregularities, followed by obesity and/or acanthosis nigricans. An abnormal 
menstrual pattern may be of little concern to the patient, but emphasizing its 
presence is critical to the diagnosis in adolescents. Some patients have an abnormal 
degree of inflammatory acne instead of hirsutism, but cutaneous symptoms of 
hyperandrogenism are not necessarily present in every patient. Although obesity is 
commonly associated with PCOS, about half of patients are not obese. 
Cutaneous manifestations 
Hirsutism — Hirsutism is defined clinically as an excessive sexual hair that appears 
in a male pattern [37]. It is a classical feature of the high androgen levels and is found 
in about two thirds of cases.Ferriman-Gallwey system, which quantitates the extent of 
hair growth in the most androgen-sensitive areas, is commonly used for grading of 
hirsutism as shown in figure 1.The score above 8 is diagnostic of 
hyperandrogenism[34]. The normal score varies with ethnicity: hirsutism is defined in 
Asian populations as a score ≥2 to 3, and in Mediterranean populations as a score ≥9 
to 10 [35].Sexual hair growth develops throughout puberty to achieve maturity by two 
years after menarche, at about 15 years of age, based on sparse normative data 
[36].“Focal hirsutism” (localized areas of hirsutism with a normal score) is a common 
cosmetic complaint.  However, not all hyperandrogenic women are hirsute because 
their pilosebaceous unit is relatively insensitive to androgens. Some of the young 
adolescents whose hyperandrogenism has not fully evolved may not be hirsute. On 
the other side, hirsutism may occur without elevated circulating levels of androgen. 
That condition is termed “idiopathic hirsutism”. [37]. 
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Figure 1.ModifiedFerriman-Gallwey scoring system [34] 
 
 
Acne — Acne vulgaris is an important cutaneous manifestation of 
hyperandrogenemia in adolescents [37]. While comedonal acne is common in 
adolescent girls, less than 5 percent of girls have comedonal acne that is moderate 
or more (>10 facial lesions) in early puberty, or have moderate or more inflammatory 
acne through the perimenarcheal years [38]. In such adolescentsthe possibility of 
hyperandrogenism should be considered,as well as for those with acne that are 
persistent and poorly responsive to topical dermatologic therapy. These patients are 
often treated with hormonal therapy for their acne which masks hyperandrogenemia 
[39]. 
Other cutaneous manifestations  
Balding is an unusual manifestation of hyperandrogenemia in adolescents.It may be 
either male-pattern (affecting the fronto-temporo-occipital scalp) or female-pattern 
(affecting the crown, typically manifesting early as a midline part widened in a 
"Christmas tree" pattern) [37]. Other cutaneous signs of androgen excess are 
seborrhea, hyperhidrosis, and hidradenitis suppurativa. 
Menstrual irregularities 
Anovulation- The distinction between abnormal and physiologic anovulation is 
frequently delayed because patients, families, and clinicians are often unsure about 
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the normal range of menstrual cycle variation in adolescents. We will mention here 
some menstrual dysfunctions that suggest abnormal degrees of anovulation in 
adolescence [40]. 
Primary amenorrhea is defined as lack of menarche by 15 years of age, or more than 
three years after the onset of breast development [40]. 
Secondary amenorrhea is defined as absence of menses for at least 90days (3 
months), after previously menstruating [40]. 
Oligomenorrhea is defined as an infrequent or very light menstruation that occurs at 
intervals over 40 days (fewer than 9 periods yearly) as an adult criterion. The criteria 
changes based on the post menarcheal years [40]. 
Dysfunctional uterine bleeding (DUB) or anovulatory abnormal uterine bleeding is 
defined as irregular (more frequently than every 21 days) or excessive (bleeding 
lasting more than seven days) vaginal bleeding [40]. 
In one study based among school population, 51 percent of girls who became 
oligomenorrheic at 15 years of age after initially menstruating regularly remained so 
at 18 years; no data exist for intervening intervals [41]. Studies of healthy schoolgirls 
have shown that menstrual irregularity [41,42] and above-average androgen levels 
are significant risk factors for PCOS or infertility in adulthood. 
Polycystic ovaries- Polycystic ovaries themselves have little clinical manifestation in 
adolescence other than their relationship to anovulation.  Among the reasons for that 
is the use of abdominal route to image ovaries by ultrasound rather than the vaginal 
one. The absence of polycystic ovaries in adolescence may also relate to the fact 
that ovarian dysfunction may not be demonstrable until 3 years after menarche [43]. 
Additional features - Obesity and clinical manifestations of insulin resistance are 
strongly associated with PCOS but are not included into diagnostic criteria. The 
clinical manifestations of insulin resistance include acanthosis nigricans, metabolic 
syndrome, sleep-disordered breathing, and nonalcoholic fatty liver disease. Insulin 
resistance is an important factor in the pathogenesis of PCOS because it has a role 
in dysregulated steroidogenesis and excessive androgen production. 
Obesity -Obesity is present in approximately half of patients with PCOS (prevalence 
varies from 30 to 75 percent) [33]. It is often the initial complaint beginning usually in 
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midchildhoodand is emphasizedduring puberty. PCOS is the most common obesity-
related endocrine syndrome in females, though the possibility exists that the 
relationship of PCOS to obesity is due to referral bias [44]. It is typically android in 
type (central adiposity defined by a waist circumference ≥88 cm) after sexual maturity 
is reached [25]. Whether the insulin resistance of PCOS is more fundamentally 
related to central obesity than global adiposity is controversial [46]. 
Clinical manifestations of insulin resistance 
The metabolic disturbances typical of adult women with PCOS are also found 
adolescents with PCOS. 
Adolescents with PCOS are at increased risk for glucose intolerance, suggesting that 
the insulin resistance is related to the pancreatic beta-cell dysfunction that is seen in 
type 2 diabetes mellitus [47]. Glucose tolerance progressively deteriorates over time: 
approximately 10 percent of women with PCOS will have type 2 diabetes mellitus by 
40 years of age [33]. American Diabetic Association (ADA) and International Diabetic 
Federation recognized PCOS as nonmodifible risk factor for type II diabetes in 
2004.[19]. 
 
Metabolic syndrome – The metabolic syndrome results from the interaction of 
insulin resistance with obesity and age. It refers to the co-occurrence of metabolic 
risk factors for type 2 diabetes mellitus and cardiovascular disease, including 
abdominal obesity, hyperglycemia, elevated triglycerides, low HDL cholesterol, and 
hypertension. Three or more of these findings confer a high risk of cardiovascular 
disease in adults [48]. There is not yet consensus about the critical levels necessary 
for the diagnosis in adolescents. 
Several interesting studies have been conveyed about connection of PCOS and 
metabolic syndrome.In the National Health and Nutrition Examination Survey 
(NHANES) report (1999 to 2000), the prevalence of the metabolic syndrome (as 
defined by the National Cholesterol Education Program/Adult Treatment Panel [ATP] 
III criteria) in normal women ages 20 to 39 years was approximately 18 to 19 percent 
[25].Using the same diagnostic criteria, Rossi et al. observed that, the prevalence 
appears to be much higher in women with PCOS: 43 percent of PCOS patients had 
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the metabolic syndrome, almost twofold higher than that of age-matched women in 
the general population, as reported by NHANES III [50]. 
A few studies among adolescents with PCOS have shown that 25 percent of them 
have metabolic syndrome which is approximately threefold higher than expected for 
age, ethnicity or BMI in the general population[25, 45].On contrary to those studies, 
one research found that 43 adolescents with PCOS( half of them obese) had similar 
rates of metabolic syndrome as compared with 31 control girls who were matched for 
weight and ethnicity but where somewhat younger than the group with PCOS [50]. 
Nevertheless, the adolescents with PCOS had evidence of significantly more insulin 
resistance.  
 
Sleep-disordered breathing – Sleep disordered breathing (SDB) is another feature 
found in adolescents with PCOS and it is usually connected with metabolic 
syndrome. In a series of mildly obese adolescents, patients with PCOS had 
significantly longer sleep latency, poorer sleep efficiency, and lower percentage of 
REM sleep as compared with BMI-matched controls, although the prevalence of 
polysomnographically-determined SDB was similar [51]. A separate series of 103 
somewhat older predominantly Hispanic-African American adolescents with PCOS 
had approximately twice the prevalence of questionnaire-determined SDB as 
compared with 90 BMI-matched controls (45 versus 27 percent) [52]. Among the 
group with PCOS, BMI was greater in those with SDB, and metabolic syndrome was 
a significant independent predictor of SDB [52]. Among a subset of these obese 
PCOS patients who underwent a sleep study, the prevalence of 
polysomnographically-determined SDB was significantly greater than in controls 
matched for age and BMI (71 versus 41 percent) and the prevalence of metabolic 
syndromewas greater. (56 versus 8 %) [52]. 
DIFFERENTIAL DIAGNOSIS 
Making a correct diagnosis of PCOS in adolescence may be a difficult task. 
Symptoms such as hirsutism, acne, menstrual irregularities and obesity are common 
during normal puberty. Three fourths of adolescent girls develop acne, and one 
quarter have inflammatory acne [53]. Similar scenario applies for irregular menstrual 
cycles which are anovulatory in half of cases during the first two postmenarchal years 
[75]. Although PCOS accounts for around 85 percent of androgen excess in 
12 
 
adolescent girls, many conditions other than PCOS present with hyperandrogenism. 
Pelvic ultrasonography and specific endocrine tests are used to distinguish among 
the many causes of hyperandrogenism that will be reviewed below. 
Virilizing congenital adrenal hyperplasia- Congenital adrenal hyperplasia (CAH) is 
an autosomal recessive disease with deficiency in the activity of an adrenocortical 
enzyme step necessary for corticosteroid biosynthesis. 
Nonclassic ("late-onset") CAH caused by mild deficiency of 21- hydroxylase is the 
second most common cause of androgen excess in adolescence.  It accounts for 2.5 
to 5 percent of cases of hyperandrogenism in most populations [54]. Compared to 
classic CAH, this one is only mildly hyperandrogenic and lacks the genital ambiguity. 
Usually it presents with premature pubarche (appearance of sexual hair), adolescent- 
or- adult onset hirsutism, and/or symptoms of anovulation. Affected females may 
have polycystic ovaries and elevated serum luteinizing hormone (LH) levels. 
Diagnosis is suggested by elevated levels of serum 17-hydroxyprogesterone (17-
OHP). CAH responds to therapy with glucocorticoid replacement [28]. 
 
Classic CAHdue to 21-hydroxylase deficiency is the most well-known form of CAH. It 
is almost always diagnosed during infancy, presenting with genital ambiguity due to 
congenital virilization of affected females, and may be associated with a salt-losing 
crisis. Individuals may develop signs and symptoms resembling PCOS during 
adolescence, especially if their disorder is poorly controlled by glucocorticoid therapy. 
Symptoms may include menstrual irregularity, hirsutism, and clitoromegaly. 
Polycystic ovaries can result from the direct effects of virilizingextraovarian androgen 
excess and from adrenal rests of the ovaries (ectopic adrenal tissue in the 
ovaries)[28]. Adrenal progesterone excess may be sufficient in the absence of 
androgen excess to cause ovarian dysfunction by inhibiting LH pulsatility [55]. 
Even in patients who are well-controlled on glucocorticoid therapy, classic CAH and, 
to a small extent, nonclassic CAH, are associated with a PCOS-type of functional 
ovarian hyperandrogenism that is responsible for persistent menstrual irregularity[28]. 
Virilizing tumors – Virilizing tumors of the adrenals or ovaries are a rare cause of 
hyperandrogenismand occur in only 0,2% of cases [56]. However, it should be 
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emphasized thatmore than half are malignant. These tumors cause rapid onset of 
virilizing symptoms, including hirsutism, temporal hair recession, increased muscle 
bulk, voice deepening, and onset of clitoromegaly without genital ambiguity. Other 
tumor manifestations may include Cushingoid changes and abdominal or pelvic 
masses. Acanthosis nigricans may occur with virilizing tumors, though it is an 
uncommon feature and more suggestive of PCOS [57].However, rapid onset of 
virilizing symptoms or high serum levels of androgens (total testosterone > 5 nmol/L) 
require thorough examination to exclude virilizing tumor. 
 
Insulin-resistance disorders – Extreme states of insulin-resistant hyperinsulinemia, 
such as congenital diabetes mellitus caused by insulin-receptor mutations (eg, 
Donohue‘s syndrome or leprechaunism) or lipodystrophy, are accompanied by 
PCOS[58].Less extreme, but still severe, insulin resistance is also linked with PCOS 
in the setting of pseudo-Cushing’s syndrome and pseudo-acromegalic gigantism, 
disorders which mimic glucocorticoid excess and childhood growth hormone excess 
clinically, without excess production of these hormones. In these disorders, the 
symptoms of insulin resistance often precede the PCOS [59]. 
In addition, mild forms of insulin resistance also are associated with PCOS, including 
type 1[60] and type 2 diabetes mellitus [61]. Elevated insulin levels seem to 
promotePCOS by increasing the activity of steroidogenic enzymes in the ovaries and 
adrenal glands, similarly to insulin-like growth factor-I (IGF-I). 
Drugs – Anabolic steroids cause virilization in women and may havecharacteristics 
similar to those of virilizing tumors. Virilizing amounts of endogenous androgens [28] 
or exogenous androgens [62] can also cause polycystic ovaries. Valproic acid directly 
enhances the transcription of the steroidogenic gene CYP17 that encodes 
cytochrome P450c17 and can cause elevated serum testosterone [63]. 
In addition to aforementioned ones, diseases that also sometimes mimic PCOS are 
Hyperprolactinemia, Cushings syndrome [64] and acromegaly [65]. 
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DIAGNOSTIC CRITERIA 
In the absence of clear etiology and pathogenesis, the diagnosis of PCOS is based 
on consensus about diagnostic criteria.At the National institutes of Health(NIH) 
consensus conference held in 1990, diagnosing of PCOS was defined as chronic 
anovulation with clinical and/or biochemical hyperandrogenism, with exclusion of 
other mimicking etiologies, such as thyroid and adrenal dysfunction. [66] In 2003, the 
Rotterdam European Society for Human Reproduction (ESHRE) / American Society 
of Reproductive Medicine (ASRM)  consensus workshop group proposed that 
diagnosis of PCOS include two of the following three criteria: oligo-and/or 
anovulation, clinical and /or biochemical hyperandrogenism, and polycystic ovaries 
on ultrasound;  other etiologies must be excluded [67]. The Rotterdam definition 
extended the diagnosis of PCOS by adding the polycystic ovaries criterion. Women 
with oligo-ovulation and polycystic ovaries (nonhyperandrogenic) as well as women 
with hyperandrogenism and polycystic ovaries (ovulatory) could be diagnosed with 
this new criteria compared to narrower NIH criteria. In 2009, The Androgen Excess 
and PCOS ( AE-PCOS) Society published  report emphasizing that PCOS is primarily 
a hyperandrogenic disorder and suggest revising the definition to hyperandrogenism 
and ovarian dysfunction, thereby involving the Rotterdam ultrasound criteria but 
requiring hyperandrogenism for the diagnosis [68].In adolescent patients, the criteria 
mentioned above present a particular diagnostic problem because characteristics of 
normal puberty often overlap with signs and symptoms of PCOS.  
Carmina and colleagues suggested that during adolescence, a definitive diagnosis of 
PCOS should require all elements of Rotterdam criteria andnot just 2 out of 3 [69]. 
The criteria proposed by these authors are stricter than their adult counterparts and 
may limit inappropriate early diagnosis but we suggest reevaluating the diagnosis 
every 6-12 months. Rotterdam diagnostic criteria is used in majority of the world 
countries as well as in Croatia and proposed strict criteria for diagnosing PCOS in 
adolescents is presented in Table 1.[3]. 
 
 
 
15 
 
 
Table 1.Suggested criteria for diagnosis of PCOS in adolescents [69]. 
Criteria Oligoanovulation Hyperandrogenism PCO-US 
Dg PCOS + + + 
Dg PCOS 
possible, not 
confirmed 
+ + - 
Dg PCOS not 
possible during 
adolescense 
+ - + 
Dg PCOS not 
possible during 
adolescense 
- + + 
Not PCOS - + - 
Not PCOS - - + 
 
Several steps that should be done for the evaluation of PCOS together with 
importance ofdiagnosing PCOS in adolescence will be discussed next. Before 
starting our diagnostic approach we need to determine who should be screened, then 
define the presence of androgen excess, rule out disorders that mimic PCOS; and 
finally determine the source of androgen excess. 
 
 
Screening for polycystic ovary syndrome 
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Screening for PCOS in adolescent girls is recommended if they fulfill one or more of 
the following characteristics: hirsutism (or hirsutism equivalent such as acne vulgaris, 
poorly responsive to topical therapies), menstrual irregularities(amenorrhea, 
oligomenorrhea or abnormal uterine bleeding) or obesity.The history and physical 
examination should start with assessment of the clinical symptoms and signs 
suggestive of polycystic ovary syndrome and for disorders that can mimic it[70]. The 
cutaneous manifestations that can be observed such as hirsutism, acne and other 
equivalents provide clinical evidence of hyperandrogenism.While mild hirsutism is 
often idiopathic, its connection with menstrual irregularities and obesity suggest 
androgen excess. The degree and distribution of sexual hair growth should be 
identified (eg, using the Ferriman-Gallwey score) and interpreted in the context of 
norms for the patient’s age and ethnicity.The history should also explore whether the 
patient shaves excess hair or uses depilatory agents, which may dim the physical 
findings, and whether the patient is taking medications that cause hirsutism (eg, 
anabolic steroids). The degree of acne should be evaluated in the context of the 
patient gynecological age. Possibility of hyperandrogenism is suggested by moderate 
or more inflammatory (>10 facial lesions) acne through the perimenarcheal years 
[53]. Acne that is persistent and poorly responsive to topical dermatologic therapy is 
an alternative indication for evaluation of PCOS. 
Furthermore, failure to establish a normal adult menstrual cycles by 2 years after 
menarchecarries a greater than two third risk of persistent oligo-ovulation 
[89].Recommendation is to start the work up at this time or sooner if the other signs 
of PCOS coexist. Although the problem of obesity is unfortunately becoming common 
among adolescents, the presence of acanthosis nigricans or a family history of 
metabolic syndrome or type 2 diabetes mellitus is also an indicator for work-up for 
PCOS [70]. 
Defining the presence of androgen excess 
The next step in diagnosing PCOS is to show an excess of androgen. Although the 
diagnostic criteria for hyperandrogenism can be based on clinical findings, 
biochemical testing establishes diagnosis more securely. This is because only about 
half cases of mild hirsutism are associated with hyperandrogenemia [34]. Moreover, 
Rosenfield and group of authorsdescribed the best laboratory choices for the 
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evidence of hyperandrogenism. They recommend initiating workup with an androgen 
panel of plasma total testosterone, free testosterone and DHEA sulfate [70]. The 
interpretation of results is sometimes complicated because some laboratories provide 
broad normal ranges for total testosterone. Results by the best current assays vary 
by an average of approximately 6 to 26 percent [9]. Reason for that lies in inaccurate 
commercial direct assays and another reason is that the general population includes 
apparently normal women with unrecognized androgen excess [71]. 
An elevation of plasma free testosterone is the best single most sensitive indicator of 
androgen excess [72]. The combination of an upper- normal total testosterone and a 
lower- normal sex hormone-binding globulin(SHBG) gives a high free testosterone 
concentration. The serum free testosterone concentration is about 50 percent higher 
in hirsute women than the total testosterone concentration. This is because they have 
relatively low level of SHBG, which is the main determinant of the fraction of serum 
free testosterone. SHBG production by the liver is raised by estrogen and 
suppressed by hyperinsulinemia of insulin resistance and by androgen excess itself 
[73]. Disadvantage of assaying free testosterone is that there is no uniform laboratory 
standard, so test specific normal ranges differ. The most reliable methods report free 
testosterone that is calculated as the product of total testosterone and a function of 
sex hormone binding globulin [74].Direct tests of the free testosterone 
serum concentration are inaccurate and should be avoided. 
The Androgen Excess-PCOS Society (AES) also recommends androgen 
measurement before beginning hormonal therapy for hirsutism [35]. 
Ultrasonography 
Performing an ultrasound for diagnosing PCOS in adolescence presents special 
difficulties. First, ovarian appearance and volume may vary during adolescence; it 
has been reported that ovaries can develop a polycystic morphology over time, and 
enlarged ovaries with a polycystic appearance can subsequently become normal in 
size[76]. Second, transabdominal approach is standard and appropriate method in 
virginal adolescent girls. Although this approach helps in screening of adrenal mass, 
it tends to underestimate the prevalence of polycystic ovaries in comparison with 
transvaginal approach used in adult women. That is particularly limited in overweight 
and obese individuals.  
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In practice it differs whether ultrasonography should be performed for all girls with 
hyperandrogenemia. Some experts perform adrenal and ovarian ultrasonography for 
all patients with anovulatory symptoms and documented hyperandrogenemia, 
primarily to exclude rare but serious androgen-producing tumors.Some other experts 
perform it only for selected patients with features that are atypical for PCOS, such as 
very high testosterone levels (eg,>5nmol/L), clitoromegaly, or rapidly progressive 
hirsutism [77]. 
The primary purpose of ultrasonography is to exclude the rare but serious adrenal or 
ovarian tumor and ovarian pathology not related to PCOS. Other pelvic pathology 
such as ovotesticular disorder of sex development and the functional 
hyperandrogenism of pregnancy can also be detected by ultrasonography [78]. Girls 
who have an ultrasound that shows an ovarian tumor or other explanation for 
hyperandrogenism should be referred for further evaluation and treatment of the 
underlying disorder.  Otherwise, hyperandrogenic girls need further endocrine studies 
irrespective of whether the ovaries are polycystic. 
 A secondary purpose of ultrasonography is to determine whether the ovaries are 
polycystic. In adolescents, the high frequency of polycystic-appearing ovaries makes 
this an unreliable criterion for the diagnosis of PCOS. 
Exclusion of other disorders that mimic polycystic ovary syndrome 
According to Rotterdam criteria, polycystic ovary syndrome is a diagnosed after 
exclusion of diseases that mimic the syndrome [67]. Therefore, the diagnosis of 
PCOS is made in hyperandrogenic adolescents who have anovulatory symptoms or 
polycystic ovaries but after we exclude other disorders with androgen excess. 
For practical purposes the endocrine screening panel and an ultrasonography 
examination are often performed at the same time as the initial testing for 
hyperandrogenemia, especially in patients with high clinical suspicion for PCOS. (eg, 
oligomenorrheic girls with moderate or severe hirsutism). 
This screening evaluation excludes most of the non-PCOS causes of 
hyperandrogenism and is consistent with the American College of Obstetricians and 
Gynecologists (ACOG) and Endocrine Society guidelines for the diagnosis of PCOS 
[75]. According to the guidelines for adults, the blood sample is used to for detection 
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of major mimicking disorders such as: congenital adrenal hyperplasia, Cushing 
syndrome, hyperprolactinemia, thyroid dysfunction and acromegaly [67-68, 75].In 
adolescents such guidelines do not exist because these disorders are less likely to 
occur than in adults.  
 Therefore, the actual range of practice varies considerably among expert clinicians 
in this field.  Some of them perform full range of screening tests for all adolescent 
patients with suspected PCOS, while some other experts select among tests based 
on clinical symptoms and signs that raise concerns about for a particular disorder.In 
the absence of a cost-effectiveness analysis, the optimal approach to the workup 
seems to be an individualized one. 
The most clinically relevant of these simple screening tests, along with the free 
testosterone at the initial evaluation for hyperandrogenemia includes a serum cortisol 
since so many patients have central obesity. Initial evaluation of patients with 
anovulatory symptoms ordinarily also includes serum luteinizing hormone (LH), 
follicle-stimulating hormone (FSH), and estradiol, as well as history about diet. 
Pregnancy should be excluded in amenorrheic patients. 
 
 
Determining the source of androgen excess 
American association of Clinical Endocrinologists guidelines (2001) recommended a 
complete evaluation of hyperandrogenism to determine the source of androgen in 
PCOS and rule out rare congenital adrenal disorders, because the treatment and 
prognosis differ [79]. The authors found that combination of dexamethasone 
suppression testing (DAST) and cosyntropintesting, will give a diagnosis of FOH or 
FAH in most patients. 
Dexamethasone is given in dosage of 0.5mg four times daily for 4 days, and the 
following morning after a final dose, free testosterone (alternatively 17- 
hydroxyprogesterone), DHEA sulfate, and cortisol are measured. Dexamethasone 
suppression of ACTH- dependent adrenal function normally causes plasma cortisol to 
fall below 1.5mcg/dl, DHEA sulfate to fall by 75% to below 80mcg/dl, and total 
testosterone to fall below 35 ng/dl [80]. 
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The DAST is interpreted on the following way: If testosterone excess 
is not suppressed by dexamethasone, but cortisol and DHEAS are suppressed 
normally, then this is typical diagnosis of PCOS. Virilizing tumors and adrenal rests 
must be considered in the presence of suggestive clinical factors. 
If neither androgen (testosterone and DHEA) excess nor corticoids are suppressed 
normally by dexamethasone, then the androgen excess may be secondary to 
Cushing syndrome, defective cortisol metabolism or noncompliance with taking 
dexamethasone. 
If both androgen and corticoids suppression are normal, an ovarian source for 
androgen is unlikely.  In that case,cosyntropin stimulation testing is recommended to 
assess 17-hydroxyprogesterone and other steroids intermediates. A clear diagnosis 
of non-classic congenital adrenal hyperplasia requires a steroid peak that is more 
than five standard deviations above average [70]. Early morning sampling is critical to 
detect the 17-OHP elevation of non-classic CAH because it wanes rapidly thereafter 
due to the diurnal variation of adrenal steroid secretion. Mildly elevated or normal 
responses to cosyntropin are consistent with FAH or idiopathic hyperandrogenism.  
 
Additional evaluation of PCOS patients 
 
Once a diagnosis of polycystic ovary syndrome (PCOS) has been established, the 
possibility of insulin resistance manifestations and quality of life issues should be 
considered. As already mentioned in paragraph with clinical features, PCOS is a risk 
factor for the early development of type 2 diabetes mellitus, metabolic syndrome, and 
their associated risks for sleep-disordered breathing, and possibly cardiovascular 
disease [81]. The proposed screening of PCOS population is summarized in Table 2. 
 
 
 
 
 
21 
 
 
Table 2. Screening of PCOS population for metabolic abnormalities [3]. 
 
 
Parents and siblings of PCOS patients are also at increased risk for metabolic 
syndrome and diabetes mellitus, particularly if they are obese. So screening is 
recommended for family members of both sexes. That can be realized by 
measurement of hemoglobin A1c or oral glucose tolerance testing [33]. 
 
THERAPY 
The question on which majority of the patients are waiting the answer for, after being 
diagnosed with PCOS sounds: “How can we treat it?” To answer on that particular 
question we need to make the clear goal of our therapy. Is that the establishment of a 
regular menstrual period or reducing in formation of androgen with the improvement 
in cosmetic problems? Are we planning to induce an ovulation, prevent the action of 
unopposed estrogen on the endometrium or we want to decrease hyperinsulinemia 
with the aim in avoidance of long term cardiovascular and metabolic consequences. 
• Every visit 
BMI (Body mass 
index) kg/m2 
• Every visit 
Waist to hip ratio 
(WHR) 
• 1x year in BMI <25 kg/m2 
• Every visit BMI >25 kg/m2 
RR  
• Every 2 years BMI< 25 kg/m2 
• Every year in BMI> 25 kg/m2 
Lipidogram 
• Every 2 years in BMI< 25 
kg/m2 
• Every year in BMI> 25 kg/m2 
OGTT 
• HOMA- IR  > 2.5 
• HOMA- IR = insulin x GUK / 
22.5 
INZULIN 0 i 120 
min 
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The universal drug and scheme for management of all the symptoms of PCOS do not 
exist, so individualized approach is used. It depends on the patient age, symptoms, 
risks and wishes for the future [70]. 
What should be unique as a first line therapy in obese individuals is a lifestyle 
modification because weight itself contributes to the worsening of all the other PCOS 
symptoms.On the other side, loss of only 5% of body mass leads to better cycle 
regulation and spontaneous ovulation. Commonly, combination of oral contraceptive 
pills (OCP) is used for the treatment in adolescents when there are expressed 
menstrual cycle disturbances, acne and mild hirsutism. (becausethey correct both 
menstrual abnormalities and hyperandrogenemia). In cases of severe hirsutism 
antiandrogen therapy is added to combination OCPs. Metformin is used as the 
therapy of choice if the abnormal glucose tolerance or lipid abnormalities cannot be 
solved just by loosing of weight. 
Treatment of hirsutism and acne 
The cornerstone of treatment of hirsutism and removal of excess hair are numerous 
cosmetic measures. Some of the most commonly used are shaving, depilation, 
bleaching and waxing techniques. They are often efficacious, relatively inexpensive 
and in general safe. Additional more expensive measures are for 
example:eflornithine hydrochloride cream (topical agent that inhibits the local hair 
growth) and laser therapy or electrolysis (thermal destruction of dermal papilla). If 
these measures are not satisfactory enough for the patient, then options are physical 
therapy, hormonal therapy or combination of the two.The decision among these 
options involves patient preference including cost of the measure, tolerance 
of discomfort/pain, risk of complications, and outcome [70]. 
Combination oral contraceptive pills 
The combination oral contraceptive pills (OCPs), which contain both estrogen and 
progestin, are the first line endocrine treatment for women with dermatologic and 
menstrual abnormalities of PCOS. This combination suppresses hypothalamic-
pituitary-ovarian axis and reduces excess androgen production by the ovary [37]. 
Result of that is improvement in menstrual irregularity, hirsutism and acne. Progestin 
component also inhibits endometrial proliferation, preventing hyperplasia and the 
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associated risk of endometrial carcinoma [90]. Those with larger estrogen doses may 
be used in larger women to provide menstrual regularity. Endocrine Society 
guidelines suggest OCPs as first-line pharmacologic therapy of menstrual irregularity 
[82] and hirsutism [34]. 
In general, it is suggested to choose OCPs that contain at least 30 µg ethinyl 
estradiol. Those OCPs containing ≤20 µg ethinyl estradiol pose lesser cardiovasular 
risk, but may inadequately promote normal growth of bone mass and may be less 
effective in controlling irregular menstrual bleeding, especially in obese 
hyperandrogenic girls [83]. There has been concern that OCPs may cause harmful 
metabolic effect in women with PCOS compared to the one without it [84]. Although 
consistent clinically significant differences in metabolic effects have not been found 
among commonly used OCPs [85]. The improvement effects on hirsutism and acne 
is primarily due to estrogenic component, and any differences  in the androgenicity of 
the progestin are minimal at these doses. The choice of the most adequate agent 
depends on the clinical picture of the individual and cost/insurance considerations. 
OCPs therapy usually normalizes androgen levels within 18-21 days. It is 
recommended to recheck patient serum free testosterone three months after 
beginning of therapy to assess the efficacy of treatment and normalization of 
androgen level. Androgen suppression is supportive of diagnosis, but not diagnostic 
[68].  
 
Antiandrogens 
Antiandrogens are used as a therapy for significant improvement of hirsutism. They 
act as competitive antagonists of steroid binding to the androgen receptor and inhibit 
the androgen- induced transformation of vellus to terminal hairs [37]. Therefore, the 
effects of these agents are not valued for 9 to 12 months due to long growth cycles of 
sexual hair follicles. All antiandrogens should be administered with oral 
contraceptives. The reason for that is their potential teratogenic feminization of the 
male fetus and they may cause menstrual disturbance. Antiandrogens also have an 
uncertain effect on metabolic abnormalities associated with PCOS [89]. 
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Spironolactone, mostly known as a weak diuretic, is the strongest antiandrogen 
available. Beside itsantiandrogenic and antimineralcorticoid effect, it is also a weak 
progestin and a weak glucocorticoid. The recommendation is to start by 100mg twice 
daily until achieving a maximal effect and then reducing the dose to 50 mg twice a 
day for maintenance therapy. Spironolactone administered in these doses is well 
tolerated, with exception of hyperkalemia that may limit its usefulness in certain 
patients, so electrolytes should be monitored. It is contraindicated in women with 
adrenal, hepatic and renal failure [69]. 
Treatment of menstrual irregularity 
Menstrual irregularities should be controlled in patients with PCOS, because chronic 
anovulation is associated with increased risk of developing endometrial hyperplasia 
and carcinoma. Major treatment options for menstrual irregularity include progestin 
and OCPs.  
Cyclic progestin can be used alone for treatment of menstrual irregularities in 
sexually mature adolescents. It relies on direct inhibitory effects on endometrial 
proliferation. Dose of micronized progesterone is 100-200 mg daily at bedtime for 7-
10 days out of each month or cycle. In most patients it will induce withdrawal 
bleeding, but some will not respond, probably because of an antiestrogenic effect of 
androgen excess on the endometrium[90]. Unlike OCPs, progestin therapy causes 
transient reduction of androgen excess but does not normalize it, what is generally 
insufficient to expect improvement in hirsutism [91]. Side effects of progestin include 
mood symptoms (depression), bloating and breast soreness. Patients must be also 
informed that oral progestin dosed in this way is not a method of contraception. 
Dysfunctional uterine bleeding (DUB) usually can be treated with cyclic progestin, but 
heavy DUB may require adding of estrogen. Treatment of heavy menstrual bleeding 
is similar in adolescents with or without PCOS. The estrogen doses required to treat 
heavy DUB may be three- to fourfold higher than the doses needed to treat irregular 
menses [92]. Estrogen can be given as OCPs, one tablet three to four times daily for 
7 days. Treatment is then stopped for 5 days, and patient should be warned that 
heavy withdrawal bleeding may occur. Usage of OCP with relatively large estrogenic 
component is preferred. Once active bleeding is controlled, therapy with cyclic OCP 
or progestin should be started to prevent recurrence of DUB. 
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Several potential limitations exist in the management of PCOS in adolescents by 
OCPs. Combination OCPs have about fourfold risk of venous thromboembolism in 
first-time users [93].Risk is related to the dose and duration of estrogen use, and to 
use of recent- generation of progestins which carry about a twofold independent risk 
[94].In patients with migraine headaches, OCPs should be used for caution and in 
the lowest possible dose [93]. Another situation where OCPs are contraindicated is in 
perimenarcheal girls with short stature and whose epiphysis are still opened 
determined by radiographic imaging. OCPs contain growth- inhibitory amounts of 
estrogen so they will bring growth of those girls to an end.For most women with 
PCOS, the benefits of oral contraceptives outweigh the potential risks of venous 
thromboembolism [70]. 
 
Treatment of obesity and insulin resistance 
It has been proven that low glycemic index diet leads to correction of hormonal and 
metabolic parameters resulting in more regular cycles and spontaneous ovulations.  
Considering that patients with PCOS are prone of gaining extra weight, it is of utmost 
importance to counsel them about healthy nutrition and low calorie intake [88]. 
The first line therapy for obese adolescents with or without diagnosis of PCOS is 
healthy diet and exercises [82]. Lifestyle modification improves menstrual frequency, 
ovulation and androgen excess. About half of obese patients who managed to lose 
weight had improvement of their symptoms [95]. 
Insulin lowering drugs, metformin and thiazolidinediones are used as adjuncts for 
treating of PCOS. Metformin acts to inhibit hepatic glucose productionand decrease 
peripheral insulin resistance.  Thiazolidinediones increase insulin sensitivity by 
promoting fat mobilization from the bloodstream. Both of these drugs stimulate 
ovulation and lower androgen levels. However, these agents are not likely to improve 
hirsutism and normalize androgen levels that are greater than two times normal [87]. 
 Metformin has the most usefulness in treating adolescents with advanced risk of 
developing PCOS (high risk ethnicity, obesity, strong family history, acanthosis 
nigricans ), because it decreases appetite and improves weight loss although to 
moderate degree [96].Therapy should be started with 500 mg daily before the 
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evening meal, with an increase in the dose by 500mg per week to the maximal dose 
of 1500-2000mg daily as tolerated [97].Result of treatment cannot be expected 
before three months.Individual that is on metformin therapy is advised to obtain 
comprehensive metabolic panel as a baseline because of rare complications of lactic 
acidosis [98].Due to that complication it is contraindicated in patients with impaired 
hepatic or renal function, alcoholism as well as cardiopulmonary insufficiency. 
Many questions remain unanswered about the use of metformin in adolescents. 
Duration of treatment and the primary indication(hyperinsulinemia vs. 
hyperandrogenemia vs. oligomenorrhea) blurs treatment guidelines. 
Multidisciplinary approach to PCOS 
There are many aspects to evaluating and treating the adolescents with PCOS, such 
as normalizing nutrition, regulating menses, addressing future concerns ( e.g. 
infertility, endometrial cancer), screening for metabolic consequences, behavioral 
counseling and modification( low self- esteem, depression, anxiety). Because all of 
the mentioned requires a lot of knowledge, time and patience to deal with, a 
multidisciplinary adolescent PCOS clinic should be established.  
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CONCLUSION 
PCOS is a serious disease with severe consequences. The formation of uniform 
guidelines is of a vital importance for the sake of establishing a clear diagnosis, 
treatment plan and follow up care. Irregular menses, anovulatory cycles, acne and 
obesity are fairly common during adolescence.Therefore, making a correct diagnosis 
in adolescent is more difficult than in adult women as the main symptoms of PCOS 
often overlap with the physiological changes that occur during puberty. With the rising 
prevalence of childhood obesity, the early identification and treatment of PCOS is of 
significant importance. Current treatment options target the specific symptoms of 
PCOS but should also include patient goals and preferences.Regular exercise, 
balanced diet and healthy way of living are of the main targets, especially in 
adolescents who have a better opportunity to establish and maintain a healthy 
lifestyle than their adult counterparts.The importance of even minor weight loss in 
obese individuals and the benefits that it has on cycle regulation and the return of 
spontaneous ovulation must have particular emphasis placed upon it. Cosmetic 
measures, hormonal contraceptives and antiandrogens are also commonly used. 
Primary prevention of long term consequences connected with PCOS such as 
diabetes mellitus, metabolic syndrome and cardiovascular disease can also be 
achieved by lifestyle modifications. Besides the advantage of treating distressing 
symptoms, early intervention aims to improve self- esteem and quality of life as a 
whole. Educating adolescents about PCOS and its risks, as well as providing 
emotional support, allows the patient to make informed choices in favor of 
establishing and maintaining a healthy lifestyle. 
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